Omzet 2024 * | 29,34 mln. 27,44 mln. | Omzet 2025 * | 90,7 mln. 84,82 mln. | Marktkapitalisatie | 189 mln. 177 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -69 mln. -64,53 mln. | Nettowinst (verlies) 2025 * | -20 mln. -18,71 mln. | EV/omzet 2024 * | 7,02 x |
Nettoschuld 2024 * | 16,8 mln. 15,71 mln. | Nettoschuld 2025 * | 14,8 mln. 13,84 mln. | EV/omzet 2025 * | 2,25 x |
K/w-verhouding 2024 * |
-2,85
x | K/w-verhouding 2025 * |
-8,75
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,7% |
Recentste transcriptie over KemPharm, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Christal Mickle
FOU | Founder | 45 | 30-10-06 |
Neil McFarlane
CEO | Chief Executive Officer | 51 | 10-10-23 |
R. Clifton
DFI | Director of Finance/CFO | 51 | 01-04-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Wendy Dixon
BRD | Director/Board Member | 68 | 25-04-23 |
Tamara Favorito
CHM | Chairman | 65 | 18-08-21 |
Director/Board Member | 56 | 25-04-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,31% | 70,44 mld. | |
+10,97% | 8,94 mld. | |
-16,83% | 4,75 mld. | |
+43,48% | 4,5 mld. | |
+3,20% | 3,85 mld. | |
+18,82% | 2,38 mld. | |
-21,36% | 2,34 mld. | |
-29,67% | 2,2 mld. | |
+8,38% | 1,96 mld. |